You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Litigation Details for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)

✉ Email this page to a colleague

« Back to Dashboard

Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)

Docket	⤷ Sign Up	Date Filed	2019-07-02
Court	District Court, D. Delaware	Date Terminated	2020-03-11
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,010,533; 10,052,385; 8,609,707; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Small Molecule Drugs cited in Teva Pharmaceuticals International GmbH v. Lupin, Ltd.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-07-02	1	Complaint	384 patent”), 10,010,533 (the “’533 patent”); and 10,052,385 (the “’385 patent”) (collectively, the …INFRINGEMENT BY LUPIN OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) …INFRINGEMENT BY LUPIN OF U.S. PATENT NO. 10,010,533 359. Plaintiffs incorporate…as the ’021 patent), and all patent rights claiming priority to those patents or patent applications …expiration of U.S. Patent Nos. 8,609,707 (the “’707 patent”); 9,265,831 (the “’831 patent”); 9,572,796 (the	External link to document
2020-03-11	25	Patent/Trademark Report to Commissioner of Patents	9,597,399 B2; US 10,010,533 B2; US 10,052,385 B2. (Attachments: # 1 Patent Report Page 2, # 2 Patent Report Page… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s)US 8,609,707 B2…2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-02	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 9,000,021 …2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-02	5	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,572,796 B2; US 9,572,797 …2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-02	6	Patent/Trademark Report to Commissioner of Patents	B2; US 9,597,399 B2; US 10,010,533 B2; US 10,052,385 B2. (nmg) (Entered: 07/03/2019) 2 July 2019 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,597,398 B2…2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.